Enhanced External Counterpulsation combined with Hyperbaric Oxygen Therapy significantly improved LVEF from 34.17% to 41.43% (p<0.001) at 6 months in patients with ischemic cardiomyopathy.
Does Enhanced External Counterpulsation (EECP) with adjunctive Hyperbaric Oxygen Therapy (HBOT) improve cardiac function and clinical outcomes in adult patients with ischemic cardiomyopathy?
The combination of EECP and HBOT added to optimal GDMT significantly improved LVEF, exercise capacity, and symptom burden in patients with ischemic cardiomyopathy at 6 months.
Absolute Event Rate: 41.43% vs 34.17%
p-value: p=<0.001
AbstractIntroduction Ischemic cardiomyopathy remains a major contributor to chronic heart failure despite optimal guideline-directed medical therapy (GDMT). HEAT HF (HBOT and EECP as Adjuvant Therapy in Heart Failure) is the first prospective study to investigate the effect of Enhanced External Counterpulsation (EECP) with adjunctive Hyperbaric Oxygen Therapy (HBOT) on enhancing cardiac function and improving clinical outcomes in patients with ischemic cardiomyopathy. Methods This prospective interventional study was conducted on 100 adult patients with ischemic cardiomyopathy left ventricular ejection fraction (LVEF) ≤50% who had undergone EECP therapy with HBOT. Data on LVEF, global longitudinal strain (GLS), NYHA class, 6-minute walk test (6MWT), NT-proBNP, serum creatinine, and heart failure-related hospitalizations were collected pre- and post-intervention. This study is an ongoing clinical trial registered with the Clinical Trials Registry - India (CTRI/2024/11/076912), registered on November 18, 2024. This analysis represents interim results at 6-month follow-up. Results There were 88% males, with a mean age of 61.5 ± 10.7 years. LVEF significantly improved from 34.17 ± 7.0 to 41.43 ± 7.0% (pConclusion EECP, combined with HBOT and optimal GDMT, significantly improves cardiac function, exercise capacity, symptom burden, and biochemical markers in ischemic cardiomyopathy. This non-invasive approach may offer a promising adjunct to standard heart failure management.
Akber et al. (Fri,) conducted a other in Ischemic cardiomyopathy (n=100). Enhanced External Counterpulsation (EECP) with adjunctive Hyperbaric Oxygen Therapy (HBOT) vs. Pre-intervention baseline was evaluated on Left ventricular ejection fraction (LVEF) (p=<0.001). Enhanced External Counterpulsation combined with Hyperbaric Oxygen Therapy significantly improved LVEF from 34.17% to 41.43% (p<0.001) at 6 months in patients with ischemic cardiomyopathy.